PTHS
Pelthos Therapeutics
$27.59
+$1.67 (+6.44%)Jul 27, 2026
Key metrics
The numbers that frame PTHS today
- Market cap
- $95.89M
- P/E (TTM)
- -1.9
- EV / FCF
- -2.7
- Gross margin
- 79.6%
- EV / Sales
- 4.2
- ROIC
- -135.6%
- Div yield
- 0%
- Debt / equity
- 1.5
- 52wk Low
- $16.50
- 52wk High
- $37.42
Growth
Revenue and earnings trend for PTHS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about PTHS
Is Pelthos Therapeutics a good buy?
Hold. Pelthos Therapeutics has strong momentum, but poor quality makes the setup mixed. Growth looks strong, which supports the long-term business case. We think Pelthos Therapeutics is selling at a very high price.
What is the market capitalization of PTHS?
Pelthos Therapeutics's market capitalization is $95.89M.
What is the P/E ratio for PTHS stock?
Pelthos Therapeutics's current P/E ratio is -1.9.
What is the 52-week high for PTHS stock?
The 52-week high for Pelthos Therapeutics is $37.42. The current close of $27.59 is 26.3% below that high.
What is the 52-week low for PTHS stock?
The 52-week low for Pelthos Therapeutics is $16.50. The current close of $27.59 is 67.2% above that low.
Does PTHS stock pay dividends?
Pelthos Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for PTHS?
Pelthos Therapeutics's Debt / Equity ratio is 1.51.